Ligand Pharmaceuticals Announces Proposed $550 Million Convertible Senior Notes Offering

Ligand Pharmaceuticals (NASDAQ:LGND) announced plans to offer $550 million in convertible senior notes due 2031 through a private placement. The company also expects to grant initial purchasers an option to buy up to an additional $82.5 million of notes within 13 days.

By Jay Mehta, SA News Editor · Seeking Alpha · June 22, 2026, 11:33 UTC

Tickers: $LGND

Topics: convertible_notes private_placement

Read the full article at Seeking Alpha

More World news

Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC
NUGL Reports Third Quarter Net Income of $0.19 Million and Revenue of $1.04 Million Seeking Alpha · November 12, 2026, 17:38 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC